Every Generic Semaglutide Brand
Available in India (2026)
Semaglutide's patent expired in India on March 20, 2026. 50+ generic brands launched within days. This is the complete, sourced guide to every approved brand — prices, formats, indications and where to get them.
AT A GLANCE
All 8 Manufacturers Compared
| Brand | Company | Est. Price | Format | Indication | Source |
|---|---|---|---|---|---|
| Noveltreat / Sematrinity | Sun Pharma | ₹750–2,000/mo | Prefilled pen | Obesity + T2D | Sun Pharma PR → |
| Obeda / Usema | Dr. Reddy's + USV | ₹4,200/mo | Prefilled pen | T2D | Pearce IP → |
| Semaglyn / Mashema / Alterme | Zydus (+ Lupin, Torrent) | ₹2,200–5,500/mo | Reusable pen | T2D + Obesity | Business Standard → |
| Semasize / Obesema / Hepaglide | Alkem Laboratories | ₹1,800–3,500/mo | Prefilled pen | T2D + Obesity | Outlook Business → |
| SUNDAE / Semanat | Eris / Natco | ₹220/shot | Vial + Pen | T2D | Business Today → |
| GLIPIQ | Glenmark | ₹325–440/week | Vial + Pen | T2D | Pearce IP → |
| Sembolic / Semalix | Torrent | TBC | Injectable + Oral | T2D + Obesity | Business Standard → |
| Samakind | Mankind | TBC | Pen | Multiple | Business Today → |
Prices indicative as of March 2026. Always verify with your pharmacist.
Noveltreat / Sematrinity
Sun PharmaIndia's largest pharma — two brands covering obesity and T2D
Noveltreat ₹900–2,000/mo · Sematrinity ₹750–1,300/mo
Format
Noveltreat: concealed needle prefilled pen · Sematrinity: multi-dose pen
Dose Strengths
0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg
Indication
Noveltreat — obesity · Sematrinity — T2D
Availability
Apollo, Netmeds, major pharmacy chains nationwide
Key Differentiator
Concealed needle design reduces injection fear. Sun Pharma has announced a patient support programme alongside both brands.
Regulatory status: DCGI approved December 2025. Phase III trial conducted in India.
Sun Pharma Press Release →Obeda / Usema
Dr. Reddy's + USVFirst DCGI approval — also licensed to USV as Usema
₹4,200/mo (Obeda) · USV pricing TBC
Format
Prefilled disposable pen — 4 weekly doses per pen
Dose Strengths
2mg, 4mg
Indication
T2D (obesity approval expected mid-2026)
Availability
Expanding through hospital and pharmacy networks
Key Differentiator
Dr Reddy's SemaKare digital support system provides injection training, therapy monitoring and tele-support. Plans to launch in 87 countries.
Regulatory status: DCGI approved. First Indian company to receive DCGI approval for generic semaglutide.
Pearce IP / Business Standard →Semaglyn / Mashema / Alterme
Zydus LifesciencesReusable pen innovation — also licensed to Lupin and Torrent
₹2,200/mo (diabetes) · ₹3,500–5,500/mo (obesity)
Format
Reusable multi-dose pen — 15mg/3ml cartridge, replace cartridges not device
Dose Strengths
Multiple strengths via single reusable device
Indication
T2D + obesity
Availability
Zydus + Lupin + Torrent distribution networks
Key Differentiator
Only reusable pen on market — allows dose adjustment during titration. Co-marketed by Lupin as Semanext/Livarise and Torrent under separate brands.
Regulatory status: DCGI approved. Exclusive agreement with pen supplier for the reusable format.
Business Standard →Semasize / Obesema / Hepaglide
Alkem LaboratoriesMost aggressive pricing — lowest cost prefilled pen in India
₹1,800/mo (diabetes) · ₹3,500/mo (obesity) — ₹450/week
Format
Disposable prefilled pen + reusable pen option (replace cartridges)
Dose Strengths
0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg
Indication
T2D + obesity (Phase III India trial completed)
Availability
Extensive distribution including Tier 2 and 3 cities
Key Differentiator
Lowest priced prefilled pen in India. Three brands cover different indications — Semasize (T2D), Obesema (obesity), Hepaglide (fatty liver/MASH — emerging indication).
Regulatory status: DCGI approved. Phase III clinical trial conducted in India.
Outlook Business →SUNDAE / Semanat
Eris Lifesciences / Natco PharmaLowest entry price in India — vial format designed for affordability
₹220/shot · ₹1,290–1,750/mo (vial) · ₹4,000–4,500/mo (pen)
Format
Multi-dose vial (available now) · Pen device (April 2026)
Dose Strengths
Multiple strengths
Indication
T2D
Availability
Hospital pharmacies. Pen device expected April 2026.
Key Differentiator
At ₹220 per shot, Eris SUNDAE has the lowest entry price of any semaglutide product globally. Glenmark Sankalp patient support programme included.
Regulatory status: Natco received CDSCO approval February 2026. Eris commercialising.
Business Today →GLIPIQ
Glenmark PharmaceuticalsVial + pen formats — Sankalp patient support programme
₹325–440/week (vial) · Pen format also available
Format
Multi-dose vial + prefilled pen
Dose Strengths
2mg/1.5ml, 4mg/3ml, 8mg/3ml
Indication
T2D
Availability
Expanding through Glenmark distribution network
Key Differentiator
Glenmark's Sankalp programme helps patients initiate and stay on therapy. Vial format enables lowest-cost entry into GLP-1 therapy.
Regulatory status: DCGI approved in both vial and prefilled pen formulations.
Pearce IP →Sembolic / Semalix
Torrent PharmaceuticalsFirst mover in oral semaglutide — injectable + oral both available
TBC
Format
Injectable + oral tablets (generic Rybelsus — all 3 dosages)
Dose Strengths
Injectable + oral 3mg, 7mg, 14mg
Indication
T2D + obesity
Availability
Torrent distribution network
Key Differentiator
Torrent is the only Indian company with oral semaglutide at launch — a generic equivalent of Rybelsus. Also has injectable via Zydus licensing agreement.
Regulatory status: DCGI approved. Only listed company to announce all three oral dosages.
Business Standard →Samakind
Mankind PharmaUnmatched Tier 2/3 city distribution — reaching smaller town India
TBC
Format
Pen
Dose Strengths
TBC
Indication
Diabetes, obesity, cardiology, orthopaedics, gynaecology
Availability
Mankind nationwide network
Key Differentiator
Mankind's strength is its Tier 2/3 city distribution network — Samakind may be the first semaglutide brand to meaningfully reach patients outside metros.
Regulatory status: DCGI approved.
Business Today →REGULATORY FRAMEWORK
CDSCO Standards & Approval
Requirements in India
India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator — equivalent to the US FDA. Every semaglutide brand on this page is DCGI-approved. Here's what that means for patients.
Schedule H Prescription Drug
Semaglutide is classified as Schedule H in India — meaning it can only be dispensed against a valid prescription from a registered medical practitioner. It cannot be purchased over the counter.
Prescription must be from an endocrinologist or internal medicine specialist. Cardiologists may prescribe for cardiovascular indications.
CDSCO / Business Standard, March 2026 →Phase III Trial Requirement
DCGI requires Indian manufacturers to submit Phase III clinical trial data from Indian patients before approval — not just bioequivalence data used for standard generics.
Sun Pharma's Noveltreat and Alkem's brands both conducted India-specific Phase III trials. This is a higher standard than most generic drug approvals.
Medical Dialogues / DCGI Approval Notice →CDSCO Approved BMI Thresholds
DCGI has approved semaglutide for obesity in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, T2D, dyslipidaemia, or sleep apnea). Note: Indian clinical guidelines (ESI, ICMR) recommend lower thresholds of BMI ≥25 — our triage tool applies these Indian-adjusted criteria.
Note: These are the approved Western thresholds. Indian clinical guidelines (ESI, ICMR) recommend lower thresholds of BMI ≥25 for Indians. Our triage tool uses Indian-adjusted criteria.
DCGI Approval — Medical Dialogues (citing CDSCO approval document) →Intensified Regulatory Surveillance
Following the March 2026 generic wave, CDSCO announced intensified surveillance against unauthorised sale and unethical marketing. Non-compliance leads to licence cancellation.
CDSCO has explicitly barred all manufacturers from promotional activities around semaglutide. This is why you will not see TV or print advertising for these brands.
Business Standard, March 24 2026 →DCGI-Approved Brands on This Page
All brands listed on GLP-1 Check have received formal approval from the Drugs Controller General of India (DCGI). We do not list unapproved or unverified products.
Beware of unapproved products
The explosion of cheap semaglutide has also created a market for counterfeit and substandard products. Only purchase from a licensed pharmacy with a valid prescription. If a price seems too low (under ₹500/month for a full dose), verify the brand's DCGI approval status before purchasing. CDSCO maintains a list of approved drugs at cdsco.gov.in →
FREQUENTLY ASKED
Questions About Indian Semaglutide Brands
Which is the cheapest semaglutide brand in India?
As of March 2026, Eris SUNDAE is available at ₹220 per shot in vial format — the globally lowest entry price. Alkem Semasize offers the lowest-priced prefilled pen at ₹1,800/month for T2D. Glenmark GLIPIQ vials start at ₹325/week. For pen devices, Zydus Semaglyn starts at ₹2,200 per month.
How many semaglutide brands are available in India in 2026?
As of March 2026, at least 8 manufacturers have launched semaglutide under 18+ brand names in India. The major ones are Noveltreat/Sematrinity (Sun Pharma), Obeda (Dr Reddy's), Semaglyn/Mashema/Alterme (Zydus), Semasize/Obesema/Hepaglide (Alkem), GLIPIQ (Glenmark), Sembolic/Semalix (Torrent), SUNDAE (Eris/Natco), and Samakind (Mankind). More than 50 total brand names are expected by end of 2026 from 40+ manufacturers.
Is Noveltreat the same as Wegovy?
Noveltreat contains the same active ingredient as Wegovy — semaglutide at 2.4mg for obesity. It is manufactured by Sun Pharma in India and approved by DCGI after a Phase III trial conducted in India.
Are all generic semaglutide brands equally effective?
All DCGI-approved generics contain the same active molecule. Approval requires bioequivalence to the reference product. Clinical efficacy should be equivalent, though device quality and cold chain handling can vary between brands.
Do I need a prescription for semaglutide in India?
Yes. Semaglutide is a Schedule H prescription drug. A valid prescription from a registered doctor is required. Self-medication is unsafe due to contraindications and the need for supervised dose escalation.
What is the difference between semaglutide for diabetes vs obesity?
The molecule is identical. Diabetes doses go up to 1mg weekly (Ozempic equivalent). Obesity treatment uses 2.4mg weekly maintenance (Wegovy equivalent). Some Indian brands are approved for both, others for one indication only.
Which brand is best for someone with both diabetes and obesity?
Noveltreat (Sun Pharma) and Semaglyn (Zydus) are approved for both T2D and obesity. Obeda (Dr Reddy's) is currently approved for T2D only. Our triage tool can help identify which indication applies to you.
Is the vial format as effective as the pen?
Yes — the semaglutide molecule is the same. The difference is administration method. Vials require drawing the medication with a syringe. Pens are pre-filled and easier for self-injection. Both deliver the same drug.
Will semaglutide prices fall further in India?
Analysts forecast 40–50% further price reduction in FY27 as competition intensifies among 50+ brands. Natco is already at ₹1,290/month — experts believe prices could fall to ₹800–1,000/month within 18 months.
Can I switch between brands?
In principle yes, but always consult your doctor before switching. Dose calibration may differ between formats (vial vs pen). Your doctor should supervise any brand change.
Where can I buy semaglutide in India?
With a valid prescription, semaglutide is available at Apollo Pharmacy, Netmeds, and major hospital pharmacies. Online pharmacies are expanding availability. Ensure you buy from a licensed pharmacy to avoid counterfeit products.
Which doctors can prescribe semaglutide in India?
CDSCO has approved semaglutide for prescription by endocrinologists and internal medicine specialists for diabetes and obesity indications. Cardiologists may prescribe for cardiovascular risk reduction indications. General physicians (GPs) are not currently authorised to prescribe semaglutide, though this may change as the market evolves.
How do I verify a semaglutide brand is DCGI-approved?
Visit cdsco.gov.in and search the approved new drugs database. All legitimate Indian generic semaglutide brands will have a DCGI approval number. You can also ask your pharmacist to show you the drug licence for the product. If in doubt, stick to well-known brands from established manufacturers.
Is it legal to buy semaglutide without a prescription in India?
No. Semaglutide is a Schedule H drug in India, which means it is illegal to sell or dispense it without a valid prescription from a registered medical practitioner. Online pharmacies selling semaglutide without a prescription are operating unlawfully. Always consult a doctor before starting treatment.
NOT SURE WHICH APPLIES TO YOU?
Check your eligibility in 5 minutes
Our triage tool determines if you are a candidate for GLP-1 therapy based on Indian clinical guidelines — free and anonymous.
Start the Assessment →